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Intracellular signaling systems of G protein-coupled recep-
tors arewell established, but their role in paracrine regulation of
adjacent cells is generally considered as a tissue-specific mech-
anism. We have shown previously that AT1 receptor (AT1R)
stimulation leads to diacylglycerol lipase-mediated transactiva-
tion of co-expressed CB1Rs in Chinese hamster ovary cells. In
the present study we detected a paracrine effect of the endocan-
nabinoid release from Chinese hamster ovary, COS7, and
HEK293 cells during the stimulation of AT1 angiotensin recep-
tors by determining CB1 cannabinoid receptor activity with
bioluminescence resonance energy transfer-based sensors of G
protein activation expressed in separate cells. The angiotensin
II-induced, paracrine activation of CB1 receptors was visualized
by detecting translocation of green fluorescent protein-tagged
-arrestin2. Mass spectrometry analyses have demonstrated
angiotensin II-induced stimulation of 2-arachidonoylglycerol
production, whereas no increase of anandamide levels was
observed. Stimulation of Gq/11-coupledM1, M3, M5muscarinic,
V1 vasopressin,1a adrenergic, B2 bradykinin receptors, but not
Gi/o-coupled M2 and M4 muscarinic receptors, also led to para-
crine transactivation of CB1 receptors. These data suggest that,
in addition to their retrograde neurotransmitter role, endocan-
nabinoids have much broader paracrine mediator functions
during activation of Gq/11-coupled receptors.
Hormones, neurotransmitters, and other chemical media-
tors acting on G protein-coupled receptors (GPCRs)2 exert
their effects on the target cells by stimulating G protein-de-
pendent and independent intracellular signaling pathways
(1–4). Activation of Gq/11 protein-coupled receptors causes
phospholipase C activation, which produces inositol-trisphos-
phate and diacylglycerol from phosphatidylinositol (4,5)-
bisphosphate, leading to Ca2-signal generation and protein
kinase C activation. However, the concerted response of tissues
to chemical mediators frequently also involves the activation of
cells adjacent to the target cells, due to the release of paracrine
mediators. A well known example is NO, which can be released
from activated endothelial cells to cause relaxation of adjacent
vascular smooth muscle cells. Lipid mediators can also act as
intercellular messengers. For example, endocannabinoids
released from postsynaptic neurons after depolarization act as
retrograde transmitters by binding to and stimulating presyn-
aptic cannabinoid receptors, which leads to inhibition of
-aminobutyric acid release (an event termed depolarization-
induced suppression of inhibition, DSI) (5–7).
Cannabinoid receptors were first identified based on their
ability to selectively recognize marijuana analogs. To date, two
cannabinoid receptors have been identified by molecular clon-
ing, CB1 andCB2 receptors (CB1R andCB2R, respectively) (5, 8,
9), although additional GPCRs have also been proposed to
function as cannabinoid receptors (10, 11). Cannabinoid recep-
tors also recognize certain lipids present in animal tissues
termed endocannabinoids, such as arachidonylethanolamide
(anandamide), 2-arachidonoylglycerol (2-AG), and 2-arachido-
noylglyceryl ether (noladin ether) (7, 12–16). In adult and fetal
neural tissues, the twomajor endocannabinoids, anandamide and
2-AG, are produced on demand, usually after depolarization of
postsynaptic cells or following stimulation ofGq-coupledmetabo-
tropic glutamate or muscarinic acetylcholine receptors (7, 12,
17–20). Enzymes responsible for 2-AG production and metabo-
lism in tissues are localized to well defined structures at synapses,
near theaxonterminalsofCB1R-expressingcells (5, 7). Incontrast,
in peripheral tissues baseline levels of endocannabinoid produc-
tion usually manifest as “endocannabinoid tone,” with poorly
understood localization of the various components of the endo-
cannabinoid system. 2-AG levels in brain homogenates and in
many peripheral tissues are near itsKd for the CB1R (19), suggest-
ing that functionof endocannabinoidsmaynot be limited to local-
ized synaptic signaling.
There is mounting evidence that endocannabinoids play
important roles in peripheral cardiovascular, inflammatory,
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intestinal, andmetabolic regulation (21–24). 2-AG is produced
by diacylglycerol-lipase (DAGL) after cleavage of the fatty-acid
in the sn-1 position of diacylglycerol (DAG) (19, 25). Phospho-
lipase C activation by Gq/11 protein-coupled receptors pro-
duces DAG, which can serve as a substrate for DAGL. Plasma
membrane phosphoinositides are enriched in arachidonic acid
in the sn-2 position (26), and DAGL is expressed ubiquitously
(27), which suggests that phospholipaseC-mediated cleavage of
polyphosphoinositides may routinely lead to the formation of
2-AG. In accordance with this hypothesis, we have recently
shown that angiotensin II- (Ang II)-mediated activation of the
Gq/11-coupledAT1angiotensinreceptor(AT1R)leadstoDAGL-
dependent activation of CB1Rs expressed in Chinese hamster
ovary (CHO) cells (28).
Here our aim has been to examine the possibility that 2-AG
serves as a common paracrine signal generated via activation of
Gq/11 protein-coupled, Ca2-mobilizing receptors. Accord-
ingly, we co-expressed CB1Rs and BRET-based sensors of G
protein activation in CHO cells, and used these cells to detect
endocannabinoid release from adjacent cells that express AT1R
or other Ca2-mobilizing GPCRs. We have further shown that
activation of AT1R by Ang II increases 2-AG levels in CHO
cells. These findings suggest that 2-AG is commonly released
following activation of Ca2-mobilizing GPCRs and serves as a
paracrine signal to activate CB1R in neighboring cells.
EXPERIMENTAL PROCEDURES
Materials—Rat o-CFP G protein subunit was kindly provided
by Dr. N. Gautam (29). Human V1 vasopressin, 1 adrenergic, B2
bradykinin andM1 muscarinic acetylcholine receptor, 1 and 11
G protein subunits were obtained from the Missouri S&T cDNA
ResourceCenter (Rolla,MO). The cDNAof the rat vascular CB1R
was provided byDr. Zsolt Lenkei (CNRS, Paris) (30).-Arrestin2-
EGFP (-arr2-GFP) was kindly provided by Dr. Marc G. Caron
(Duke University, Durham, NC) (31).
Plasmid Constructs and Transfection—RFP-tagged CB1R
was constructed by subcloning the CB1R cDNA into an mRFP
containing vector (provided by Dr. R. Tsien, University of Cal-
ifornia, San Diego, CA). EYFP-1 was generated by subcloning
human 1 subunit into the mammalian expression vector
pEYFP-C1 (Clontech). o-Rluc was constructed by replacing
the CFP coding region in o-CFP with Renilla luciferase. Rat
HA-AT1R receptor and AT1-EYFP were constructed as
described earlier (32). AT1R-Cerulean was constructed by
replacing the cDNAof EYFPwith Cerulean coding region (pro-
vided by Dr. R. Tsien). CHO cells were transfected with Lipo-
fectamine 2000 according to manufacturer’s suggestions using
2 or 16–24 g of DNA and 2 or 16 l of Lipofectamine 2000 in
6-well plates or 100-mm tissue culture plates, respectively.
CHO cells were maintained in Ham’s F-12 supplemented with
10% fetal bovine serum, 100 g/ml streptomycin, and 100
IU/ml penicillin. COS-7 kidney fibroblast cells and HEK293
human embryonic fibroblast cells were grown in complete Dul-
becco’s modified Eagle’s medium containing glucose, gluta-
mine, sodium bicarbonate, and supplemented with 10% fetal
bovine serum, 100 g/ml streptomycin, 100 IU/ml penicillin.
Site-directed Mutagenesis—Mutations in the rat CB1R
(D214A and R215A) were performed with the QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA) accord-
ing to the manufacturer’s suggestions and verified using auto-
mated sequencing.
Confocal Laser-scanning Microscopy—CHO cells were
grown on glass coverslips and transfected with labeled CB1R
and AT1R and GFP-labeled -arrestin2, as described above,
48 h prior to measurement. In transactivation experiments, the
cells were detached with Versene 1 day after transfection; the
indicated cells were mixed and placed back to coverslips. Ceru-
lean, EGFP, andRFPwere excitedwith the 458 and 488 nm lines
of the argon laser and the 543 nm line of the helium/neon laser,
respectively; their emitted fluorescence was detected in multi-
track mode with 480–520 nm, 500–530 nm band pass and 560
nm long pass filters, respectively. Because GFP caused a weak
cross-talk in this setup in the 480–520 nm band pass channel
used for Cerulean, the full images showing Cerulean were cor-
rected for the cross-talk of the GFP signals.
BRET Assay of G Protein Activation—Energy transfer
between G protein subunits was measured using o G protein
subunit fused with Renilla luciferase (o-Rluc) and 1 subunit
labeled with enhanced yellow fluorescent protein (EYFP-1).
Medium was changed to fetal bovine serum-supplemented
Ham’s F-12 6 h following transfection and incubated overnight.
Before the experiments the cells were detached with Versene
and centrifuged. Cells were suspended in a modified Krebs-
Ringer buffer containing (in mM): 120 NaCl, 4.7 KCl, 1.2 CaCl2,
0.7 MgSO4, 10 glucose, 10 sodium Hepes, pH 7.4 (containing 1
g/liter albumin in paracrine transactivation studies) and trans-
ferred to white 96-well plates. The cell density was between
100,000 and 200,000 cells/well. Coelenterazine hwas added to a
final concentration of 5M, and readings were collected using a
Mithras LB 940Multilabel Reader (Berthold Technologies, Bad
Wildbad, Germany). BRET ratio was defined as (emission at
530 nm)/(emission at 485), and the normalized BRET ratio was
calculated as the BRET ratio for the co-expressed EYFP-tagged
and Rluc-tagged molecules minus the BRET ratio for the co-
expressed non-tagged and Rluc-tagged molecules. Data for G
protein activity are shown as the percent changes in normalized
BRET ratios compared with themean of the four control BRET
ratio points before the first stimulation (BRET ratio, percent of
control).
Measurement of 2-AG and Anandamide Levels—CHO cells
transfectedwithAT1Rweremaintained inHam’s F-12medium
in 10-cm tissue culture plates as described above. Aliquots of
4 106 cells in 10-cm tissue culture plates containing 3.5 ml of
modified Krebs-Ringer buffer were incubated with vehicle or
100 nM angiotensin II for the indicated times, following which
the cells plus medium were extracted in 2 volumes of ice-cold
chloroform:methanol (2:1, v/v) containing 7 ng of 4H2-anand-
amide as internal standard. The chloroform phase was sepa-
rated and re-extracted twice and finally dried under a stream of
nitrogen. The dried residuewas reconstructed in 100l of chlo-
roform, deproteinated with 2 ml of ice-cold acetone, centri-
fuged, and the clear supernatant was evaporated to dryness.
Samples were resuspended in 50 l of methanol for analysis of
endocannabinoid content by liquid chromatography/in line
mass spectrometry, as described (33).
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Statistical Analysis—All data are presented as means  S.E.
Differences between groups were analyzed by one- or two-way
repeated measures analysis of variance combined with Holm-
Sidak test using the software SigmaStat forWindows 3.5 (Systat
Software Inc., Richmond, CA). The value of p 0.05 was con-
sidered significant.
RESULTS
Stimulation of AT1Rs Expressed in CHO,HEK, andCOSCells
Leads to Paracrine Transactivation of CB1Rs—We have previ-
ously shown thatCB1R can be transactivatedwithAng II in cells
co-expressing CB1R and AT1R (28). We therefore postulated
that, if the transactivation of CB1R was caused by a released
endocannabinoid, it would also occur if AT1R and CB1R were
expressed in separate, adjacent cells. To examine this possibil-
ity, we monitored the activation of CB1Rs expressed in CHO
cells to detect Ang II-induced endocannabinoid release by
other cells mixed to the cells expressing CB1R. CB1R activity
was quantified by detecting bioluminescence resonance energy
transfer (BRET) between Go protein subunits (Renilla lucif-
erase-tagged o and EYFP-tagged 1, o-Rluc, and EYFP-1,
respectively) as described previously (28). In this experimental
setting, activation of CB1R leads to a decrease of the BRET
signal resulting from the dissociation of activated Go protein
subunits, whereas inactivation by an antagonist increases the
BRET signal, because it leads to the association of G protein
subunits (28, 29). CHO cells were transfected either with
expression plasmids of AT1R, or were co-transfected with plas-
mids of CB1R and tagged G protein subunits. Twenty-four
hours later, the cells weremixed and
CB1R activity was measured
by detecting BRET interaction
between G protein subunits, as a
way to monitor endocannabinoid
release. Stimulation of the cells with
Ang II led to a decrease in BRET sig-
nal indicating activation of CB1R
(Fig. 1A, filled circles). Administra-
tion of the CB1R inverse agonist
AM251 caused an increase in the
BRET signal, reflecting the inhibition
of the basal activity of the receptor.
AM251 also blocked the Ang II-in-
duced transactivation (Fig. 1A, open
circles). A slight baseline shift of the
BRET signal occurred during treat-
ment, which might have been
caused by the small increase in vol-
ume; and the kinetics of the
response was too fast to analyze its
initial phase with manual stimula-
tion. Therefore, an automated injec-
tor was used in separate experi-
ments to analyze the initial phase of
the Ang II-induced response in
higher time-resolution (Fig. 1,B and
C). The initial baseline shift
occurred promptly both in control
and stimulated cells. In Ang II-stimulated cells (filled circles)
after a lag time of15–20 s the BRET signal decreased rapidly
(Fig. 1B), which was not observed in cells treated with medium
(control cells, open squares). AM251 fully prevented the effect
of Ang II stimulation on the BRET signal (Fig. 1C).
When AT1R-transfected cells weremixed with cells express-
ing the Go sensor, but no CB1R, Go protein activation did not
occur, which provides additional evidence that it was mediated
through CB1R (Fig. 1D). Similarly, when cells expressing CB1R,
but not AT1R, were stimulated with Ang II, the BRET signal
remained unaffected (Fig. 1E). In other experiments, the origi-
nal 1:1 ratio of AT1R or CB1R-expressing cells was increased to
5:1 or decreased to 0.1:1, keeping the number of CB1R-express-
ing cells constant at 100,000 cells/well, which resulted in a cor-
responding increase or decrease, respectively, in Go protein
activation, approaching a plateau between 1:1 and 5:1 cell ratios
(Fig. 1F). These findings suggest that Go protein activation in
CB1R-expressing cells was mediated by Ang II-induced endo-
cannabinoid release from CHO cells expressing AT1R. Trans-
activation of CB1R was also inhibited by pretreatment of the
cells expressing AT1R with the DAGL inhibitor tetrahydrolip-
statin (1 M) (Fig. 2A, open triangles), suggesting that DAGL
plays a role in the process. Statistical analysis of the data is
shown in Fig. 2B.
Transactivation of CHO cells expressing CB1Rs was also
detected when these cells were mixed with equal number of
HEK293 or COS7 cells expressing AT1Rs, and stimulated with
Ang II. These data demonstrate that the AT1R-mediated para-
crine transactivation of CB1Rs is not restricted to CHO cells
FIGURE 1. Effects of AT1R and CB1R ligands on Go protein subunit association measured by BRET. CHO
cells expressing AT1R were mixed with equal quantities of cells expressing CB1R and Go protein subunits and
CB1R activitywasmeasuredbyBRET.A, BRET changes are shown inCHOcells treatedwith vehicle (veh) - vehicle
(empty squares), Ang II-WIN (100 nM, filled circles) and AM251-Ang II (10M, empty circles) (n 5). B and C, BRET
values are shown in higher time resolution in vehicle (B)- and AM251-pretreated (C) cells (n 3).D and E, BRET
change is shown in vehicle-AM (open squares) and Ang II-WIN55-stimulated (filled circles) cells when cells
expressing AT1R were mixed with cells expressing Go probe but no CB1R (D) and when cells expressing only
CB1R and Go probewere stimulated (E). F, constant numbers of cells expressing CB1Rweremixedwith increas-
ing number of cells expressing AT1R and change in CB1R activity was expressed as compared with vehicle
treated cells. Relative activity was calculated from BRET ratio values compared with those following WIN55 (1
M) treatment (n 3). Arrows show the time points for the indicated single (B and C) or sequential (A,D, and E)
treatments.
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and may be a common mechanism in different cell types (Fig.
3). Slightly increased transactivation of CB1Rs was observed,
when these AT1R-expressing cells were added in a 5-fold
excess, suggesting that the response was almost maximal under
these conditions (supplemental Fig. S1).
AT1R Activation Leads to -Arrestin Translocation to CB1R
in Adjacent Cells—To provide additional evidence that Ang
II-induced activation of AT1R leads to the formation and
release of endocannabinoids, -arrestin translocation to trans-
activated CB1Rs was measured in CHO cells. -Arrestin cou-
pling to GPCRs has often been used as an indicator of receptor
activation (31, 32, 34). When RFP-tagged CB1R (CB1R-RFP)
was co-expressed with GFP-tagged -arrestin2 (-arr2GFP),
CB1R-RFP localized both to the cell membrane and to intracel-
lular vesicles (Fig. 4A), which is consistent with the previously
reported constitutive internalization of this receptor, which
may be caused by constitutive receptor activity, endocannabi-
noid formation, or other mechanisms (28, 30, 35). Following
stimulation with the synthetic cannabinoid agonist WIN
55,212-2, -arr2-GFP translocated to the activated CB1Rs at
the cell surface, and was detected in punctate structures at the
plasma membrane (Fig. 4A). The conserved DRY motif in the
second intracellular loop of GPCRs has been previously impli-
cated in -arrestin binding of some GPCRs (36–38). In other
GPCRs, mutations in the conserved DRY region caused
enhanced -arrestin binding (39, 40). The enhanced -arrestin
binding of these receptors may be caused by their reduced G
protein coupling (41–43). We have generated mutations in the
conserved DRY motif within the second intracellular loop of
CB1R (D214A and R215A) (CB1R[DRY/AAY]). To study the
interaction of the mutant CB1R with -arrestin, RFP-tagged
CB1R(DRY/AAY) (CB1R(DRY/AAY)-RFP) was co-expressed
with -arr2-GFP in CHO cells. In non-stimulated cells, -arr2-
GFP was distributed diffusely in the cytoplasm, but basal activ-
ity of thismutantCB1R caused its appearance in punctate struc-
tures at the plasma membrane (Fig. 4B, left). Stimulation with
WIN55,212-2 caused robust translocation of-arr2-GFP to the
plasmamembrane, with only very faint fluorescence remaining
in the cytoplasm (Fig. 4B,middle). These data demonstrate that
co-expression of CB1R(DRY/AAY)-RFP with -arr2-GFP is a
sensitive tool for visualization of both basal and agonist-in-
duced CB1R activity.
To test if endocannabinoid release could be detected by
-arr2-GFP translocation to CB1R, CB1R(DRY/AAY)-RFP and
-arr2-GFP were co-expressed in CHO cells, and a separate
pool of cells were transfected independently with AT1R-Ceru-
lean. Twenty-four hours after transfection, the cells weremixed
and placed on coverslips, and another day later they were visu-
alized using confocal microscopy. As shown in Fig. 5, after Ang
II-induced stimulation of the mixed CHO cell population
expressing CB1R(DRY/AAY)-RFP and -arr2-GFP or AT1R-
Cerulean, translocation of -arr2-GFP to the plasma mem-
brane was observed in cells expressing CB1R(DRY/AAY)-RFP.
This response was observed in 67 7% of cells (n 3, 86 cells
total) with neighboring AT1R-Cerulean-expressing cells;
whereas in parallel experiments, when cells expressing
CB1R(DRY/AAY)-RFP and -arr2-GFP were stimulated with
Ang II in the absence of AT1R-expressing cells, no transloca-
tion of -arr2-GFP was detected (Fig. 4C). These data provide
additional evidence that a paracrine endocannabinoid media-
tor is released as a result of AT1R activation.
2-AG Formation Is Enhanced by Stimulation of AT1Rs—To
verify whether the Ang II-induced decrease in BRET signal
detected by confocal microscopy was, in fact, due to endocan-
nabinoid release, we measured 2-AG and anandamide levels in
control and Ang II-stimulated AT1R-expressing cells. As
shown in Fig. 6, stimulation of cells with Ang II caused a statis-
tically significant sustained elevation of 2-AG levels with simi-
lar kinetics to that of CB1R transac-
tivation measured with BRET (Fig.
1A). Anandamide levels were very
low and did not show statistically
significant changes in response to
Ang II stimulation (supplemental
Fig. S2.). These data are consistent
with our hypothesis that Gq/11-me-
diated DAG formation serves as a
source of endocannabinoid release
and suggest that the endocannabi-
noid involved in Ang II-induced
paracrine CB1R transactivation is
2-AG.
CB1R Transactivation by AT1R
Receptor Stimulation Is Not De-
FIGURE 2. DAG lipase inhibitor (tetrahydrolipstatin) prevents paracrine
transactivationofCB1RbyAT1R.A, cells expressingAT1Rwerepretreatedwith
1Mtetrahydrolipstatin for15minbeforethestartof theexperiment,mixedwith
CB1R-expressing cells andwere immediatelymoved to plates to start the exper-
iment. Cells were treated sequentially with vehicle and AM251 (10 M, filled
squares), orwithAng II (100nM)andWIN55 (1M,open triangles) (n3). The time
of treatments are indicatedby arrows.B, quantificationof dataonpanel AonFig.
1 and panel A on Fig. 2: mean values of five time points after first stimulation
compared with average levels of five measurements before stimulation (100%)
(n 3; *, p 0.05).
FIGURE 3.Paracrine transactivation of CB1RbyAT1R activation inHEK293 andCOS7 cells.HEK293 (A) and
COS7 (B) cells expressing AT1R were mixed with CHO cells expressing CB1R and Go protein subunits and CB1R
activity was measured by BRET. Cells were stimulated with Ang II (100 nM), and BRET signal decreased (filled
circles) compared with control cells (empty squares). AM251 treatment (10 M) increased the BRET signal and
prevented the Ang II induced decrease (empty circles). C, quantification of data on panels A and B: mean values
of five time points after first stimulation compared with average levels of five measurements before stimula-
tion (100%) (n 3; *, p 0.01). The arrows show the time of the indicated treatments.
Paracrine Transactivation of CB1R by AT1R
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pendent on Intracellular Ca2 Signal Generation—2-AG pro-
duction in neural cells can be stimulated either by the Ca2
signal caused by activation of ionotropic receptors, by stimula-
tion of Gq activating (metabotropic) cholinergic or glutamater-
gic receptors, or by the coincidence of two signals (44). 2-AG
production can be stimulated in cultured cell lines overexpress-
ing DAGLs by inducing a Ca2 signal with ionomycin (27, 44).
Therefore we asked if transactivation of CB1R by AT1R is
dependent on Ca2. In control cells, G protein activation
occurred after Ang II stimulation and a Ca2 signal was
detected (Fig. 7, A and D). In cells preincubated with 1,2-
bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid tet-
rakis(acetoxymethyl ester) (BAPTA-AM; 60 M) and pre-
loaded with FURA-2, Ang II-induced Ca2 elevation was not
detected even though transactivation of CB1R still occurred
(Fig. 7,B andD).Moreover, administration of ionomycin (1M)
was not able to fully mimic the effect of AT1R stimulation,
although a small, reproducible, but in this set of experiments
statistically not significant Go protein activation was detectable
(Fig. 7, C andD). The averaged BRET data are presented in Fig.
7D. Because, under these conditions, ionomycin causes larger
elevations of cytoplasmic [Ca2] than those caused by Ang II
(Fig. 7,A andC, inset), these results suggest that transactivation
was not primarily mediated by intracellular Ca2 elevation.
Gq/11-coupled GPCRs Cause Paracrine Transactivation of
CB1R—It has been demonstrated previously that activation of
Gq-coupled muscarinic or metabotropic glutamate receptors
induces endocannabinoid release in neurons (17–19). To test if
endocannabinoid release common occurs after stimulation of
Gq-coupled receptors, we expressed M1, M3, and M5 choliner-
gic (M1R, M3R, and M5R, respectively), V1 vasopressin (V1R),
1A adrenergic (1AAR), and B2 bradykinin (B2R) receptors in
CHO cells, and tested if paracrine transactivation of CB1R
occurs. We also tested the effect of stimulation of Gi/o-coupled
M2 and M4 muscarinic cholinergic receptors (M2R and M4R,
respectively). Gq/11- or Gi/o-activating receptors were ex-
pressed in one set of cells, and CB1R and Go sensor were
expressed in separate population of cells. The two populations
of cellsweremixed and stimulatedwith the appropriate ligands.
As shown in Fig. 8, CB1R was transactivated when Gq/11 pro-
tein-activating M1R, M3R, M5R, 1AAR, V1R, or B2R-express-
ing cells were stimulated with the appropriate ligands, but no
transactivation was detected when Gi/o protein-coupled M2R
or M4R were stimulated. The degree of transactivation in the
former groups was similar to that measured with cells express-
ing AT1R (Fig. 2B). Transactivation did not occur in the
absence of either CB1R or the Gq/11-activating receptor (sup-
plemental Fig. S3). These findings demonstrate that paracrine
CB1R transactivation by endocannabinoids is not specific to
AT1R and can be also initiated in cells that express other Gq/11-
activating GPCRs.
DISCUSSION
Seven transmembraneGPCRs constitute the largest group of
membrane receptors (45). They respond to a large variety of
stimuli and transduce various signals across the plasma mem-
brane by coupling to heterotrimeric G proteins (46, 47). There
are about 1000 GPCRs in the human genome, and about half of
the medications used in current clinical practice modify the
biological activity of GPCRs (48, 49). Stimulation of GPCRs
leads to activation of heterotrimeric G proteins (50) composed
of , , and  subunits, and GPCR activation causes dissocia-
tion or conformational rearrangement of the  subunit from
the  complex (51). This is followed by intracellular responses
depending on the composition of the heterotrimer. In the case
of Gq/11-coupled receptors, such as the AT1R, early events
include cleavage of phosphatidylinositol 1,4,5-bisphosphate by
phospholipase C and formation of secondmessengers such as
inositol 1,4,5-trisphosphate and DAG (2, 3). Inositol 1,4,5-
trisphosphate initiates Ca2 release from intracellular stores,
whereas DAG activates protein kinase C (52). BecauseDAG is a
common signalingmolecule in different cell types andDAGL is
found in almost every tissue (27), we hypothesized that 2-AG
FIGURE 4. Confocal analysis of -arr2-GFP coupling to CB1R in CHO
cells. A, CB1R-RFP and-arr2-GFP localization in control (upper panels) and
WIN55 stimulated cells (lower panels). B, -arr2-GFP localization in control
and stimulated cells expressing CB1R(DRY/AAY)-RFP. Cells were treated
withWIN55 (1M) and AM251 (10M). C,-arr2-GFP localization in control
(left), Ang II (middle), and WIN55 (right) stimulated cells coexpressing
CB1R(DRY/AAY)-RFP.
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formation can be a common early signaling event in most cells.
To detect the formation and release of endocannabinoids as a
general consequence of Gq/11 protein activation, we expressed
AT1R in CHO, HEK293, and COS7 cell lines, which do not
express cannabinoid receptors constitutively.
CHO cells expressing CB1R and a Gi/o BRET sensor were
used to monitor endocannabinoid release (28, 29, 51). Mixing
these cells with cells expressing other GPCRs allowed us to
detect the endocannabinoid release
caused by these GPCRs. An advan-
tage of using these sensors is that
the signal is less affected by the rapid
degradation of endocannabinoids.
Our findings clearly indicate that
activation of AT1Rs leads to endo-
cannabinoid formation and release,
with the subsequent activation of
CB1Rs. Our data also indicate that
activation of Gq/11-coupled recep-
tors can cause paracrine activation
of adjacent cells, because in our
experiments the stimulated Gq/11-
coupled receptors and the CB1R
were expressed in different cells.
We have also demonstrated that
Ang II increased the level of 2-AG in
CHO cells expressing AT1R. In con-
trol cells, 2-AG was also detected,
which is consistentwith the possible
role of this molecule in the basal
activity of CB1R (28). These data
support our hypothesis that theAng
II-inducedDAGL-dependent trans-
activation of CB1Rs is mediated by
2-AG. Therefore, 2-AG is the most
likely candidate tomediate the observed paracrine effects in our
cells. The release of endocannabinoids from cells may occur
via unidentified transporter molecules, which is consistent
with their proposed paracrine mediator role (53). However,
we could not detect transactivation when the supernatant
from the stimulated cell population was transferred to cells
expressing CB1Rs.3 It is possible that endocannabinoids,
being lipophilic molecules, remain membrane-associated
and require direct contact with adjacent CB1R-expressing
cells for receptor activation.
We have also tested other Gq/11-activating GPCRs, including
muscarinic acetylcholine receptors, which are known to cause
2-AG release in neural tissues, aswell as1ARs, V1Rs, andB2Rs.
Our data suggest that 2-AG release is a common consequence
of the activation of various Gq/11-coupled receptors. Because
2-AG can be released by cells (54), its release can cause para-
crine regulation of adjacent cells. Based on our data we propose
that activation of Gq/11-coupled receptors results in a coordi-
nated intracellular (inositol 1,4,5-trisphosphate and DAG) and
intercellular (2-AG) signaling, and the phospholipase C-cata-
lyzed hydrolysis of polyphosphoinositides serves as a source of
both types of messengers.
Blockade or stimulation of cannabinoid receptors has wide-
ranging effects in a number of organ systems, including brain,
cardiovascular system, adipose tissue, liver, immune system,
and the eye (12, 21, 22). The present results indicate that endo-
cannabinoid activation of CB1R can also be triggered indirectly
via Gq/11-coupled receptors, which means that the primary
3 G. Turu and L. Hunyady, unpublished observation.
FIGURE 5. Visualization of AT1R-mediated paracrine transactivation of CB1R using -arr2-GFP. AT1R-
Cerulean-expressing cells (see C, G, and K) were mixed with those transfected with CB1R(DRY/AAY)-RFP and
-arr2-GFP (see A, E, I, B, F, and J), and were placed on coverslips. Cells were treated with 100 nM Ang II (E, F, G,
and H), followed by stimulation with WIN55,212-2 (I, J, K, and L). The arrows in panel F point at -arr2-GFP
translocated to the membrane of cells expressing CB1Rs. Merged images are presented in panels D, H, and L.
FIGURE 6. Effect of Ang II on 2-AG levels in CHO cells expressing AT1Rs.
CHO cells (4 million cells/10-cm tissue culture plates with 3.5 ml of medium)
expressingAT1Rwere treatedwith100nMAngII for indicated times, and lipids
were extracted from cells and the medium. Tissue levels of 2-AG was quanti-
fied by liquid chromatography/in-linemass spectrometry and statistical anal-
ysis of the data with analysis of variance was performed as described under
“Experimental Procedures” (n 3; *, p 0.05; **, p 0.01).
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response to agonists of these receptors can be modulated by
endocannabinoids. Furthermore, some of the physiological
effects observed followingCB1 receptor blockademay be due to
removal of such amodulation of tonically activeGq/11-coupled
receptor signaling. Furthermore, these data also suggest that
endocannabinoid production is not restricted to small, well
defined regions/tissues in the organism, but is a general prop-
erty of many, if not all, tissues. Although CB1R is expressed
mainly in the central nervous system, it is also found in many
peripheral tissues, and stimulation or blocking of these recep-
tors has marked effects on their function (12, 21, 22).
In addition, 2-AG released as a paracrine mediator may acti-
vate CB2R, because it is a full agonist at both CB1R and CB2R
(19) and may also activate additional receptors (12). We have
also testedwhetherGq protein activation leads to endocannabi-
noid release in different types of cell lines. CHO cells are ovar-
ian, whereas HEK293 cells are from the kidney and COS cells
are fibroblasts. We detected CB1R activation after stimulation
of Gq protein-activating AT1R expressed in all three cell lines
tested and also following stimulation of other Gq protein-acti-
vating receptors transfected into these cells. This strongly sug-
gests that endocannabinoid release is not dependent of cell type
or specific Gq/11-coupled receptors and may be a general prop-
erty of all tissues upon Gq protein activation. Endocannabinoid
release triggered by activation ofGq/11-coupled receptors could
be inhibited by a DAGL inhibitor, suggesting that the underly-
ingmechanismwas an increase in the DAGL-catalyzed hydrol-
ysis of DAG to yield 2-AG. However, we cannot exclude the
alternative possibility that the increased cellular levels of 2-AG
result, at least in part, from inhibition of its degradation via
monoacylglycerol lipase. Thus, the magnitude of the basal
FIGURE7.TransactivationofCB1RbycoexpressedAT1R is independentof
cytoplasmic Ca2 signal generation. CB1R activity was measured by BRET
between Go protein subunits in cells coexpressing CB1R and AT1R. Insets: to
study the cytoplasmic Ca2 signal generation, the cells were loaded with
FURA 2 for 45 min, and Ca2 was measured in suspended cells by detecting
the ratio of fluorescent emissions ratio at 510 nm during excitation at two
wavelengths (380/340 nm). A, cells were treated with vehicle (veh, empty
squares) or Ang II (100 nM, filled circles) at the time indicated by the first arrow,
and BRET signal was measured in cells expressing CB1R. At the second arrow
the Ang II-stimulated cells were also treated with WIN55 (1 M). B, cells
expressing the same constructs were preloadedwith 60MBAPTA-AM for 45
min on room temperature, and Go activation was measured. C, the effect of
ionomycin (1 M) on Go protein activation in cells expressing the Go protein
sensors.D, quantification of data in A–C: mean values of five time points after
stimulationwith vehicle (white bars), Ang II or ionomycin (black bars) (n 3; *,
p 0.01).
FIGURE 8. Paracrine transactivation of CB1R by different GPCRs.M1-, M2-,
M3-, M4-, and M5, AchR, 1AR, B2, V1 receptor-expressing cells were mixed
with cells expressing CB1R and Go protein subunits as described under
“Experimental Procedures,” and CB1R activity was measured by BRET after
simulation with the corresponding agonists (carbachol (10 M), phenyleph-
rine (100M), bradykinin (100nM), andAVP (100nM)).Meanvalues of five time
points after stimulation with vehicle or agonists (black bars) are presented
(n3, *p0.01,).p values: 0.002 (M1R), 0.604 (M2R), below0.001 (M3R), 0.489
(M4R), below0.001 (M5R), below0.001 (1-AR), below0.001 (B2R), below0.001
(V1R).
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“endocannabinoid tone” and endocannabinoid release may
depend on relative activity of these enzymes.
In conclusion, our data show that 2-AG formation and
release is a general paracrine signaling mechanism of Gq/11-
coupled GPCRs. Based on these results we propose that, in
addition to inositol 1,4,5-trisphosphate- and DAG-mediated
intracellular signaling, 2-AG formed from the DAG generated
during activation of Gq/11 proteins is released and acts as a
paracrine signal for cannabinoid receptors on adjacent cells,
which would modulate the primary response to Ca2-mobiliz-
ing hormones in a region-specific manner. Because 2-AG has
been implicated in a variety of physiological functions and the
enzymes responsible for its biosynthesis are present in most
tissues, we are proposing that the previously recognized retro-
grade transmitter role of endocannabinoids is part of a much
broader paracrine signaling role of these mediators.
Acknowledgment—The excellent technical assistance of Judit Bakac-
sine´ Ra´cz is greatly appreciated.
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